IRVINE, Calif., Nov. 7, 2012 /PRNewswire/ -- AtheroNova Inc.
(OTCBB: AHRO), a biotech company focused on the research and
development of compounds to safely regress atherosclerotic plaque
and improve lipid profiles in humans, today announced that
Fred Knoll, the principal and
portfolio manager of Knoll Capital Management, has been named to
the Board of Directors of AtheroNova Inc.
"As a leading investment manager, Fred brings a wealth of
knowledge in emerging growth companies and will bring his expertise
to our many opportunities as we transition into the next phase of
clinical development at AtheroNova," stated Thomas W. Gardner, CEO of AtheroNova. "We
welcome Fred to our Board and look forward to working together as
we develop AtheroNova's atherosclerosis regression and lipid
modulation technology."
Since 1987, Mr. Knoll has been the principal and portfolio
manager at Knoll Capital Management, an investment company managing
funds over the last two decades in areas such as emerging growth
companies, restructurings and China. During the 80's and
early 90's, he was Chairman of the Board of Directors of Telos
Corporation, a computer systems integration company, served as
investment manager for General American Investors, was the United States representative on
investments in leveraged buyouts and venture capital for
Murray Johnstone, Ltd. of
Glasgow, UK , and headed the
New York investment group of
Robert Fleming, Inc., at the time, a
leading United Kingdom merchant
bank subsequently acquired by JP Morgan, managing a venture capital
fund and the U.S. research team.
Mr. Knoll started his investment career as an investment analyst
at Capital Research (Capital Group) in the early 80s and held
positions in sales and marketing with Wang Inc. and Data General
and software engineering with Computer Sciences Corporation in the
late 70s.
Mr. Knoll holds a Bachelor's of Science in Electrical
Engineering and Computer Science from Massachusetts Institute of Technology (M.I.T.), a
Bachelor's of Science in Management from the Sloan School at
M.I.T., and a M.B.A. from Columbia
University in Finance and was a member of the Columbia University International Fellows
Program.
About AtheroNova
AtheroNova Inc., through its
wholly-owned subsidiary, AtheroNova Operations, Inc., is a
biotechnology company focused on the discovery, research,
development and licensing of novel compounds to reduce or regress
atherosclerotic plaque deposits and to safely improve lipid
profiles in humans. In addition to its lead compound AHRO-001,
AtheroNova plans to develop multiple applications for its
patents-pending therapies in market sectors that include:
Cardiovascular Disease, Stroke, Peripheral Artery Disease, Dementia
and Alzheimer's and Erectile Dysfunction, all of which have been
linked to atherosclerosis. Atherosclerosis and its related
pharmaceutical expenses for these indications cost consumers more
than $41 billion annually in
the United States alone. For more
information, please visit www.AtheroNova.com.
Forward-Looking Statements
Except for historical
information contained herein, the statements in this release are
forward-looking and made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are inherently unreliable and actual
results may differ materially. Examples of forward-looking
statements in this news release include statements regarding the
value of Mr. Knoll's appointment to AtheroNova's board, and the
development of applications for AtheroNova's technology.
Factors which could cause actual results to differ materially
from these forward-looking statements include such factors as
significant fluctuations in expenses associated with clinical
trials, failure to secure additional financing, the inability to
complete regulatory filings with the Food and Drug Administration,
the introduction of competing products, or management's ability to
attract and maintain qualified personnel necessary for the
development and commercialization of its planned products, and
other information that may be detailed from time to time in
AtheroNova's filings with the United States Securities and Exchange
Commission. AtheroNova undertakes no obligation to publicly update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
SOURCE AtheroNova Inc.